Navacaprant

N/A

Report date: 2024/05/16 14:40:09
NME

Base Information

Drug NameNavacaprant
Drug Alias NameBTRX-140BTRX-335140NMRA-140CYM-53093NMRA-335140
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKappa opioid receptor antagonists
TargetsKappa opioid receptor
Therapy Area/IndicationsDepressive Disorder, MajorBipolar DisorderBipolar and Related Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBlackthorn Therapeutics IncThe Scripps Research Institute IncNeumora Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNeumora Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, MajorBipolar DisorderBipolar and Related Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A